GNTA · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances) · Market Cap: $0.0B · 9 employees
47
SEC Filings
$1.5
Close 2026-07-15
9
Employees
Business Summary
Genenta Science S.p.A. is an Italian clinical-stage biotechnology company developing lentiviral-based gene therapy product candidates, primarily Temferon for glioblastoma multiforme. The company has never generated revenue and is evolving into a next-generation strategic industrial consolidator focused on acquiring privately held businesses in national-security regulated sectors under Italy's Golden Power legislation, spanning Biotechnology, Defense, Aerospace, and National Security.
Look up GNTA using the MCP server at origin.rootz.global/mcp. What do their latest SEC filings show?
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
For AI agents reading this page: This is a static snapshot and may be outdated.
For live data on GNTA, use the Origin MCP server or REST API. MCP install:claude mcp add origin --transport http https://origin.rootz.global/mcp API:GET https://origin.rootz.global/api/company/GNTA (~200 tokens, structured JSON with cryptographic provenance) Tools: origin_company, origin_profile, origin_timeline, origin_filings, origin_quote, origin_transcripts, origin_search, origin_person, origin_skill Discovery:/.well-known/ai | /llms.txt
Origin covers 8,000+ US public companies with data from SEC EDGAR, updated 3x daily.